Same-day HIV pill restart after NNRTI stop
Part of Immune system & allergy, Infections clinical trials.
This trial tests switching back to a single-pill HIV treatment (B/F/TAF) for people who stopped a different type of HIV medicine (called an NNRTI) at least 90 days ago. It aims to see if restarting the same day is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You stopped your previous NNRTI HIV medicine more than 90 days ago.
- Your kidneys and liver are working well (no severe problems).
- You are not resistant to the study drug bictegravir (BIC).
- You are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the medication Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) for people with HIV who have stopped taking their antiretroviral therapy (ART) for at least 12 weeks and are ready to restart treatment. It aims to see how well the medication works when restarting care.
This study compares two HIV medications (DTG/3TC and BIC/TAF/FTC) to see which works better and is safer for people who have never taken HIV treatment before. It may help you find a once-daily pill that controls the virus and has fewer side effects.
This study tests whether switching your current HIV medication to a daily pill with doravirine, dolutegravir, and lamivudine is safe and effective. It is for people whose HIV is well-controlled but who have had to change treatment before because it stopped working.
This study tests whether switching to a new three-drug HIV combination (bictegravir, emtricitabine, and tenofovir alafenamide) works safely and effectively for people whose HIV became resistant to cabotegravir/rilpivirine injections. Researchers will compare outcomes in people who make this switch.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This study tests a newer HIV medication, B/F/TAF, as a first-line treatment. It compares B/F/TAF with older combinations (TDF+3TC+EFV or DTG/3TC) to see how well it works for people who have never taken HIV meds.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.